High quality, high margin, low cost African GACP cultivator poised for immediate and rapid growth!
Largest licensed cultivator in Africa! GACP, IMC-GAP, strong South Africa and U.S.-based ownership group, high-THC cultivars and industry-low cost structure will allow this global cannabis company to thrive under future price compression
Listing ID:
16412209311
Licence(s) Held:
Lesotho Operation Licence, IMC-GAP, GACP and CUMCS Certifications
Seeking “smart money” strategic partner to invest up to $3 million USD; open to Board representation
Listing Details:
Well established, high margin, high quality, cannabis cultivator & exporter of medical THC flower poised for exponential growth
First-to-market for export of medical cannabis out of Africa; strategically positioned as a prime cornerstone within the global supply chain for premium, new trend cultivars
Led by an experienced South Africa and U.S.-based ownership group, world-class industry leaders and operational teams, the company boasts an industry low overhead cost structure and tax benefits
Currently undertaking cultivation, genetics/tissue culture, trimming, drying, propagation and bulk packaging, B2B sales and export into Israel
Company owns the largest medical cultivation cannabis licence in Africa with an initial high quality, state-of-the-art, 80,000 ft.² greenhouse, nestled within 370 acres of land
The site encompasses a new ~8500 ft.² post-harvest manufacturing facility adhering to EU GMP standards, as well as a centralized operation hub
The greenhouse facility possesses the capacity to yield 10,000 kg of premium dried flower annually
Established four premium, high quality cultivars, showcasing THC levels of 22% to 24.5% (to balance current global demand and restrictions regarding THC content.) In addition, efforts are underway to propagate additional unique strains.
In negotiations with several new purchase agreements and has strong commercial distribution leads in Australia, Germany, Poland, and South Africa
Largest physical footprint as the licence can accommodate 30 greenhouses plus vast outdoor grow
Anticipate pursuing EU GMP certification within the next 18 months. With the inclusion of a strategic partner, this process could be expedited within a shorter timeframe.
An exceptional prospect to collaborate with one of Africa's top-tier, dominant cultivators, presenting the opportunity to capture a substantial share of the market
Leveraging well-established infrastructure, attractive labor dynamics, gateway into the market and a pro-business, pro-cannabis governmental stance, the company provides a compelling proposition
Looking for “smart money” investors/partners characterized by strategic acumen, particularly those with a strong international presence, ideally within the EU
16412209311
NEW CANNABIS BUSINESSES FOR SALE
See the latest cannabis business listings on the market including dispensaries, cultivation facilities, greenhouses, labs, and more. If you're looking to invest, acquire, or expand, these business opportunities provide the perfect starting point to grow your footprint in the cannabis industry.
29345918591
State-of-the-art, ~130,000 sq. ft. production facility with 20.5 tonnes annual capacity and & EU-GMP designed processing hub
Opportunity to acquire a custom-designed, ~130,000 sq. ft. turnkey production asset including 84,000 square feet of canopy designed for pharmaceutical-grade output. This unique opportunity allows for a clean-slate acquisition of world-class infrastructure providing an immediate entry point into the global medicinal and premium international markets.
45967461758
Leading online patient acquisition & retention platform: 20,000+ active patient ecosystem and full Canadian regulatory compliance
Purpose-built for high-efficiency patient acquisition and retention within the Canadian medical cannabis sector, this low-overhead, tech-enabled platform provides a high-margin gateway for LPs and healthcare practitioners seeking to scale their patient bases quickly. Designed with scalability in mind, the platform is poised to expand into adjacent care segments and international markets
